|
|
|
16.07.25 - 14:09
|
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 (Business Wire)
|
|
|
The Company to host an earnings conference call via webcastAUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Tuesday, July 29th, 2025, at 10:30AM ET.
The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at https://ir.ipather...
|
|
|
|
|
07.07.25 - 15:06
|
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.
Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies.
“We are pleased to welcome Jon to IPA's Board of Directors during this transformative period for the Company,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “Jon brings the rare and highly valuable combination of Nasdaq board governance and senior execut...
|
|
|
|
|
|
|
|
|
28.03.25 - 13:06
|
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 (Business Wire)
|
|
|
Secures $8-$10M Strategic Partnership
Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery.
Unlocking Margin Expansion Through Scalable AI
IPA Strengthens Board & Management Team
Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations.
AUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter (“Q3”) of its 2025 fiscal year (“FY25”), which ended January 31, 2025.
"As we continue to revolutionize the AI-enabled drug discovery sector, our recent milestones underscore the growing recognition of our innovative AI and growth potential. Notably, we've secured a strategic partnership valued at $8-10 million USD with a leading biotech company, leveraging our proprietary B-cell Select ...
|
|
|
|
|
|
|
12.03.25 - 03:21
|
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 (Business Wire)
|
|
|
The Company to host an earnings conference call via webcast
AUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day.
The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, March 28, 2025, at 10:30...
|
|
|
05.03.25 - 14:06
|
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 (Business Wire)
|
|
|
The Company to host an earnings conference call via webcast
AUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, March 13, 2025, at 10:30AM ET.
The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default....
|
|
|
|
|
24.02.25 - 14:03
|
ImmunoPrecise Antibodies Announces Key Leadership Changes (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors.
Kamil Isaev Joins IPA's Board of Directors
IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its Board of Directors. With over 30 years of expertise in AI, semiconductor technologies, and global R&D operations, Isaev has held leadership roles at Intel, Dell EMC, Align Technology, and ABRT VC. His career has been defined by scaling R&D centers, driving AI-driven innovation, and leading high-impact cross-functional teams to bring emerging technologies to market.
Isaev currently serves as a Venture Partner at ABRT VC, where he...
|
|
|
|
|
27.01.25 - 14:03
|
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture (Business Wire)
|
|
|
IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for GrowthAUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) (NASDAQ: IPA), a leader in AI-driven antibody discovery and development, today announced the successful completion of its previously disclosed USD $8.8 million “at-the-market” equity offering program (the “ATM Program”) alongside the full conversion of its outstanding debenture with Yorkville Advisors, significantly enhancing the Company's capital structure.
Strategic ATM Offering Raises USD $7.0 Million
Utilizing their ATM program, the Company generated approximately USD $7.0 million in gross proceeds. The Company utilized the ATM strategically, enabling them to dramatically reduce the cost of capital while reinforcing their financial position.
"The successful execution of our ATM Program underscores investor confidence in IPA's vision and technology," said Dr. Jennifer Bath, CEO of ...
|
|
|
|
|
|
|
01.01.25 - 01:57
|
IPA Announces Resignation of Chief Financial Officer (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time.
“Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors."
IPA has initiated a CFO succession process and will provide updates as appropriate.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Com...
|
|
|
23.12.24 - 15:57
|
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases (Business Wire)
|
|
|
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company's strategic direction and long-term potential through substantial share purchases.
Over the past week, CEO Dr. Jennifer Bath and BioStrand co-founders Dirk Van Hyfte and Ingrid Brands collectively acquired a total of 763,120 shares of IPA on the open market for an aggregate amount of USD $306,000.
A Strong Signal of Confidence
This insider activity highlights the leadership team's belief in IPA's growth trajectory and transformational initiatives. Dr. Bath commented, “Our collective investments reflect our deep confidence in IPA's vision and our commitment to driving long-term value for our shareholders. As we advance groundbreaking initiatives in...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
